Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

26.30 +0.40 (+1.54%)
Official Closing Price Updated: 7:00 PM EST, Feb 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
99 100 Next >
FDA move illuminates key role of telomere targeting as a viable therapeutic strategy for cancer treatment
Via AB Newswire
Exposures COVID-19 Product Safety
Healthcare Stocks Continue To Lag The Market-Can Anything Help ?
Healthcare stocks continue to lag the market up about 6% YTD, helped by Large Cap Biopharma but hurt by United Health. 
Via Talk Markets
Pfizer's RSV Vaccine Abrysvo Clears Concerns Over Preterm Birth Risk, Safety For Pregnant Women, New Study Shows
Pfizer's RSV vaccine, Abrysvo, for pregnant women shows no increased risk of pre-term births, according to a study. Researchers found no significant difference in pre-term birth rates between... 
Via Benzinga
3 Overlooked Giants-in-the-Making for Patient Investors
Consider buying into these overlooked growth stocks for long-term profits that will help to boost a portfolio and deliver riches. 
Via InvestorPlace
What the Options Market Tells Us About Pfizer
Via Benzinga
Want $1,000 in Dividend Income? Here's How Much You Have to Invest in Pfizer Stock
Don't ignore this drugmaker simply because it's been unable to come up with a full replacement for Lipitor. 
Via The Motley Fool
Down 55%, Is Pfizer a Good Dividend Stock to Buy on the Dip?
Shares of the world's largest drugmaker offer a dividend yield above 6% at recent prices. 
Via The Motley Fool
EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO
The GLP-1 drug market for obesity treatment is expected to skyrocket to $1 trillion or more, according to Maurits Pot, founder and CEO of Tema ETFs. 
Via Benzinga
Topics ETFs
3 Bargain Stocks With the Potential for Mind-Boggling Returns
Discover three bargain stocks leading in healthcare and pharmaceuticals with fundamentals behind their potential for massive returns. 
Via InvestorPlace
MarketBeat Week in Review – 7/1 - 7/5
The market was mostly quiet in a holiday-shortened week; that may change next week with the latest inflation readings and the kickoff of a new earnings season 
Via MarketBeat
Topics Economy
Exposures Interest Rates
3 Reliable Dividend Stocks With Yields Above 5% You Can Buy With $100 in July
Adding these dividend payers to your portfolio is a nearly certain way to boost your passive income stream. 
Via The Motley Fool
Ozempic Maker Novo Nordisk Reprimanded by UK Regulators for Payment Disclosure Failures
UK regulators reprimand Novo Nordisk for failing to disclose nearly $10 million in fees and expenses. The PMCPA cites breaches in financial categorization and highlights similar issues with Novartis... 
Via Benzinga
3 Stock Giants Analysts Are Bullish On Despite Struggles
Despite recent struggles, PYPL, BABA, and PFE present attractive opportunities with favorable P/Es, high dividend yields, and analyst-predicted upsides. 
Via MarketBeat
3 Dividend Stocks That Are Screaming Buys in July
Income-seeking investors will want to move on these stocks sooner rather than later. 
Via The Motley Fool
Upcoming Stock Spinoffs: Should You Pounce or Pass?
Stock spinoffs are a unique opportunity to pick up unloved, unwanted businesses but patience is often needed before buying in. 
Via InvestorPlace
7 Juicy Dividend Stocks That Have Grown for More Than a Decade
These long-term dividend growth stocks offer relatively juicy yields above 4% along with overall stability, 
Via InvestorPlace
How To Buy Growth Stocks In An Economy That Isn’t Growing
The S&P 500 and Nasdaq both hit record highs today - in a shortened, not-very-exciting trading session. 
Via Talk Markets
Topics Economy Stocks
Exposures Economy US Equities
AbbVie Stock: A Perfect Dip for Investors to Buy
ABBV stock is down over 3% to start the second half of the year; the stock may be overvalued in the short term but still offers value for long-term investors 
Via MarketBeat
Topics ETFs
3 Undervalued Stocks Poised for a Jaw-Dropping Breakout
These three undervalued stocks have immense potential for a jaw-dropping breakout, offering triple-digit upside in the coming years. 
Via InvestorPlace
GSK Buys Full Rights To Investigational Covid-19 And Influenza Vaccines From CureVac For Around $1.5B
GSK and CureVac restructured their collaboration into a new licensing agreement, prioritizing mRNA vaccine development. GSK gains full control of vaccine candidates for influenza and COVID-19, while... 
Via Benzinga
Exposures COVID-19
Altimmune Stock: Is Its GLP-1 Drug the Next Ozempic Killer?
Clinical-state biopharmaceutical company Altimmune Inc. (NASDAQ: ALT) focuses on developing peptide-based therapeutics for obesity and chronic liver diseases 
Via MarketBeat
Exposures Product Safety
London High Court Ruling Fuels Pfizer And Moderna Legal Dispute Over COVID-19 Vaccine Patents
Pfizer and Moderna continue their legal battle over COVID-19 vaccine patents following a mixed ruling by London's High Court, with potential appeals on the horizon and significant financial stakes... 
Via Benzinga
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex
The biotech sector (IBB) is trading just 3% away from its 52-week high and a significant resistance level, suggesting a potential breakout. 
Via MarketBeat
Topics ETFs
Exposures COVID-19
Heartburn Drug Zantac Litigation: GSK And Other Pharma Giants Face Trial Over Cancer Claims
A Delaware judge dismissed GSK and other drugmakers' appeal, allowing over 70,000 lawsuits alleging Zantac causes cancer to proceed, with the companies needing Delaware Supreme Court approval to... 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Pfizer Stock is Ready to Stage a Turnaround on GLP-1 Hopes
Pharmaceutical giant Pfizer Inc. (NYSE: PFE) has been trying to enter the weight-loss treatment trend dominated by GLP-1 drug makers like Ozempic and Wegovy 
Via MarketBeat
1 Underwhelming Stat That May Have You Thinking Twice About Buying Pfizer's Stock
Pfizer's valuation looks attractive, but that doesn't mean the stock is a lock to outperform the broader market. 
Via The Motley Fool
3 Under-the-Radar Biotech Stocks With Blockbuster Potential
Are you looking to boost your portfolio with the best under-the-radar biotech stocks? Here are the top three. 
Via InvestorPlace
Time to Pounce: 2 Ultra-High-Yield Dividend Stocks That Are Begging to Be Bought for the Second Half of 2024 (and Beyond)
Two high-octane income stocks, which are premier companies sporting 6% yields within their respective industries, are historically cheap and ripe for the picking. 
Via The Motley Fool
Surprise! 3 Stocks That Are Outperforming Nvidia in 2024.
There are more marketplace opportunities than just AI which is why these stocks that are outperforming Nvidia have done so well. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Amazon Web Services Focuses On The Future, Anticipating AI Challenges Years In Advance To Deliver 'True Value' For Customers
Amazon is taking an all-encompassing approach to enterprise AI in an effort to better deliver the tools that customers need when they need them. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback